225 related articles for article (PubMed ID: 30130401)
1. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
3. Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
S El Salamouni N; Buckley BJ; Jiang L; Huang M; Ranson M; Kelso MJ; Yu H
J Med Chem; 2022 Feb; 65(3):1933-1945. PubMed ID: 34898192
[TBL] [Abstract][Full Text] [Related]
4. 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
Buckley BJ; Majed H; Aboelela A; Minaei E; Jiang L; Fildes K; Cheung CY; Johnson D; Bachovchin D; Cook GM; Huang M; Ranson M; Kelso MJ
Bioorg Med Chem Lett; 2019 Dec; 29(24):126753. PubMed ID: 31679971
[TBL] [Abstract][Full Text] [Related]
5. Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
Buckley BJ; Aboelela A; Majed H; Bujaroski RS; White KL; Powell AK; Wang W; Katneni K; Saunders J; Shackleford DM; Charman SA; Cook GM; Kelso MJ; Ranson M
Bioorg Med Chem; 2021 May; 37():116116. PubMed ID: 33799173
[TBL] [Abstract][Full Text] [Related]
6. Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Buckley BJ; Kumar A; Aboelela A; Bujaroski RS; Li X; Majed H; Fliegel L; Ranson M; Kelso MJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804289
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
8. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
10. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
11. 2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
Massey AP; Harley WR; Pasupuleti N; Gorin FA; Nantz MH
Bioorg Med Chem Lett; 2012 Apr; 22(7):2635-9. PubMed ID: 22366654
[TBL] [Abstract][Full Text] [Related]
12. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Ray P; Bhatti R; Gadarowski J; Bell N; Nasruddin S
Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
[TBL] [Abstract][Full Text] [Related]
15. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
El Salamouni NS; Buckley BJ; Ranson M; Kelso MJ; Yu H
Biophys Rev; 2022 Feb; 14(1):277-301. PubMed ID: 35340592
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?
Matthews H; Ranson M; Kelso MJ
Int J Cancer; 2011 Nov; 129(9):2051-61. PubMed ID: 21544803
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Wang D; Yang Y; Jiang L; Wang Y; Li J; Andreasen PA; Chen Z; Huang M; Xu P
J Med Chem; 2019 Feb; 62(4):2172-2183. PubMed ID: 30707839
[TBL] [Abstract][Full Text] [Related]
19. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
20. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]